期刊文献+

急性心力衰竭心肾阳虚证生物学标志物与预后相关性研究 被引量:3

Correlation between Biomarkers and Prognosis of Acute Heart Failure Patients with Heart-kidney Yang-deficiency Syndrome
下载PDF
导出
摘要 目的:探讨急性心力衰竭心肾阳虚证患者生物学标志物与预后的相关性。方法:观察129例急性心力衰竭心肾阳虚证患者肌酐(Cr)、月光抑素C(CysC)、B型利钠肤(BNP)、肌钙蛋白I(eTnI)、肾小球滤过率(eGFR)水平,并随访2年,评价生物学标志物与预后的相关性。结果:急性心力衰竭心肾阳虚证患者2年内死亡者CysC水平显著高于未死亡者(P<0.05),而Cr、BNP、eTnI、eGFR水平无显著差异。结论:血CysC浓度可以作为评估急性心衰心肾阳虚证患者2年生存率的重要生物学标志物。 Objective: To investigate the correlation between biomarkers and prognosis of acute heart failure patients with heart-kidney yang-deficiency syndrome. Methods. A total of 129 acute heart failure patients with heart-kidney yang-deficiency syndrome received the blood testing for creatinine(Cr), cystatin C(CysC), B-type natriuretic peptide(BNP) and cardiac troponin I(cTnl). Besides the estimated glomerular filtration rate(eGFR) was calculated. The correlation between these biomarkers and 2-year prognosis was analyzed. Results. The level of CysC in patients who died within two years was much higher than those who were alive(P 〈 0.05). However, there were no statistic difference between two groups in the level of Cr, BNP and cTnl. Conclusion: The level of CysC is positively correlated with the 2-year prognosis of acute heart failure patients with heart-kidney yang-deficiency syndrome.
作者 朱贤慧
出处 《新中医》 CAS 2015年第10期21-24,共4页 New Chinese Medicine
关键词 急性心力衰竭 心肾阳虚证 生物学标志物 胱抑素C 预后 Acute Heart failure Heart-kidney yang-deficiency syndrome, Biomarkers: Cystatin C(CysC) Prognosis
  • 相关文献

参考文献11

  • 1中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122. 被引量:4662
  • 2急性心力衰竭诊断和治疗指南[J].中华心血管病杂志,2010,38(3):195-208. 被引量:836
  • 3中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:54-58.
  • 4Levey AS, Stevens LA, Schmid CH, et al. CKD- EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate [J]. Ann Intern Med, 2009, 150(9): 604-612.
  • 5黄敏华,徐燕,姚成增,符德玉,徐帮杰,周宇芳,赵燕燕.慢性心力衰竭心气虚、心阳虚、心肾阳虚3个不同病程阶段中医药干预临床研究[J].辽宁中医杂志,2014,41(6):1095-1098. 被引量:27
  • 6Angelidis C, Deftereos S, Giannopoulos G, et al. Cystatin C: anemerging biomarker in cardiovascular disease[J]. Curr Top Med Chem, 2013, 13(2): 164- 179.
  • 7Inker LA, Okparavero A. Cystatin C as a marker of glom erular filtration rate: prospects and limitations [J]. Curr Opin Nephrol Hypertens, 2011, 20(6): 631-639.
  • 8Kim H, Yoon H J, Park HS, et al. Potentials of cystatin C and uric acid for predicting prognosis of heart fail- ure[J]. Congest Heart Fail, 2013, 19(3): 123-129.
  • 9Zamora E, Lup6n J, de Antonio M, et al. Long-term prognostic value for patients with chronic heart failure of estimated gtomerular filtration rate calculated with the new CKD-EPI equations containing cystatin C[J]. Clin Chem, 2014, 60(3): 481-489.
  • 10Tousoulis D, Michalea S, Siasos G, et al. Cystatin-C serum levels and vascular function in heart failure[J]. Int J Cardiol, 2014, 173(3): 542-544.

二级参考文献49

  • 1谢洪智,朱文玲.重组人脑利钠肽和硝酸甘油治疗急性失代偿性心力衰竭疗效和安全性的随机、开放、平行对照的多中心临床研究[J].中华心血管病杂志,2006,34(3):222-226. 被引量:228
  • 2中华医学会心血管病学分会 中华心血管病杂志编辑委员会.β肾上腺素能受体阻滞剂在心血管疾病应用的专家共识[J].中华心血管病杂志,2009,37:195-209.
  • 3中华医学会心血管病学分会 中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗建议.中华心血管病杂志,2007,35(12):1076-1095.
  • 4Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26: 384-416.
  • 5Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 : the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC ( HFA ) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J, 2008, 29 : 2388-2442.
  • 6Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines ( Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure ). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart fa/lure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ( Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol, 2005, 46: e1-e82.
  • 7Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Aduks: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines : developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation, 2009, 119: 1977-2016.
  • 8Liang KV, Williams AW, Greene EL, et al. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med, 2008, 36(1 Suppl) : S75-S88.
  • 9Chen D, Assad-Kottner C, Orrego C, et al. Cytokines and acute heart failure. Crit Care Med, 2008, 36(1 Suppl) : S9-S16.
  • 10Chen AA, Wood MJ, Krauser DG, et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J, 2006, 27 : 839-845.

共引文献6719

同被引文献55

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部